Estimated prevalence of human papillomavirus among Nigerian women: A systematic review and meta-analysis

Onyemaechi Anoruo, Claire Bristow, Nisha Mody, Jeffrey D. Klausner

Abstract

HPV prevalence in Nigeria has been challenging to quantify given regional population heterogeneity and differences in diagnostic methodology.  We conducted a systematic review and meta-analysis of 17 studies, each of which summarized HPV prevalence in women residing in six geopolitical zones of Nigeria. The estimated pooled prevalence (effect size) of HPV in Nigeria was 32% (CI: 23-41%). HPV prevalence was 29% (CI: 20-39%) among studies that detected HPV by genotype. HPV prevalence among studies that used serologic detection was 38% (CI: 12-65%). When stratified by region, a study in the South East (SE) geopolitical zone reported the highest prevalence of 71% (CI: 61-80%) while a study in the South South (SS) geopolitical zone reported the lowest prevalence of 4.9% (CI: 3-9%). HPV prevalence in Nigeria was high. Heterogeneity between study regions and differing HPV detection methods both contribute to variation in estimates. Using pooled estimates serves to inform future strategies for epidemiologic surveillance and future design of HPV and cervical cancer prevention initiatives. (Afr J Reprod Health 2022; 26[6]:89-96).

Full Text:

PDF

References

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018.

Small W, Bacon M, Bajaj A, Chuang L, Fisher B, Harkenrider M, Jhingran A, Kitchener H, Mileshkin LR, Viswanathan A and Gaffney D. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404-2412.

Human Papillomavirus (HPV) and Cervical Cancer. World Health Organization Fact Sheet, World Health Organization, 24 Jan. 2019. Webpage: www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Last accessed 8 August 2020.

Clifford G, Gallus S, Herrero R, Muñoz N, Snijders P, Vaccarella S, Anh H, Ferreccio K, Hieu N, Matos E, Molano M, Rajkumar R, Ronco G, De Sanjosé S, Shin H, Sukvirach S, Thomas J, Tunsakal S, Meijer M and Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991-8.

Adebamowo S, Dareng E, Famooto A, Odutola M, Bakare B and Adebamowo C. Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME's) Human Papillomavirus (HPV) and Cervical Cancer Study. Int J Epidemiol. 2017;46(6):1745-1745j.

Adebamowo S, Olawande O, Famooto A, Dareng E, Offiong R and Adebamowo C. Persistent Low-Risk and High-Risk Human Papillomavirus Infections of the Uterine Cervix in HIV-Negative and HIV-Positive Women. Front Public Health. 2017; 5:178.

Akarolo-Anthony S, Famooto A, Dareng E, Olaniyan O, Offiong R, Wheeler C and Adebamowo C. Age-specific prevalence of human papilloma virus infection among Nigerian women. BMC Public Health. 2014; 14:656.

Famooto A, Almujtaba M, Dareng E, Akarolo-Anthony S, Ogbonna C, Offiong R, Olaniyan O, Wheeler C, Doumatey A, Rotimi C, Adeyemo A and Adebamowo C. RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus Infection in Nigerian Women. PLoS ONE. 2013;8(6):e66930.

Modibbo F, Iregbu K, Okuma J, Leeman A, Annemieke Kasius, De Koning M, Quint W and Adebamowo C. Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria. Infect Agents Cancer. 2017; 12:11.

Manga M, Fowotade A, Abdullahi Y, El-Nafatyt A, Adamu D, Pidiga HU, Bakare R and Osoba A. Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria. Infect Agents Cancer. 2015; 10:39.

Aminu M, Gwafan J, Inabo H, Oguntayo A, Ella E and Koledade A. Seroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria. Int J Womens Health. 2014; 6:479-87.

Auwal I, Aminu M, Atanda A, Tukur J and Sarkinfada F. Prevalence and risk factors of high risk human papillomavirus infections among women attending gynaecology clinics in Kano, northern Nigeria. Bayero Journal of Pure and Applied Sciences 2013:6(1):67-71.

Pimentel V, Jiang X, Mandavilli S, Umenyi-Nwana C and Schnatz P. Prevalence of high-risk cervical human papillomavirus and squamous intraepithelial lesion in Nigeria. J Low Genit Tract Dis. 2013;17(2):203-9.

Kennedy N, Ikechukwu D and Goddy B. Risk factors and distribution of oncogenic strains of human papilloma virus in women presenting for cervical cancer screening in Port Harcourt, Nigeria. Pan Afr Med J. 2016; 23:85.

Okonko I and Ofoedu V. Prevalence of IgG Antibodies against Human Papillomavirus (HPV) type 6, 11, 16, and 18 Virus-Like Particles in Women of Childbearing Age in Port Harcourt, Nigeria. J Immunoassay Immunochem. 2015;36(6):622-38.

Ngwu B and Ezeifeka G. The seroprevalence of Human Papilloma Virus (HPV) types 6,11,16 and 18 among women attending cervical screening (Pap smear) service in Abakaliki, southeastern Nigeria. British Microbiology Research Journal 2015:7(6):306-312.

Adekunle S, Sule W and Oluwayelu D. High negativity of IgG antibodies against human papillomavirus type 6, 11, 16 and 18 virus-like particles in healthy women of childbearing age. Journal of Experimental and Integrative Medicine. 2014:4(1):37-41.

Fadahunsi O, Omoniyi-Esan G and Banjo B. Prevalence of high risk HPV in cervical smear of women in Ile-Ife. International Journal of Gynecological Cancer. 2013:23(8): 361.

Gage J, Ajenifuja K, Wentzensen N, Adepiti A, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman A, Burk R and Schiffman M. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer. 2012;130(9):2111-7.

Kolawole O, Olatunji K, Durowade K, Adeniyi A and Omokanye L. Prevalence, risk factors of human papillomavirus infection and papanicolaou smear pattern among women attending a tertiary health facility in south-west Nigeria. TAF Preventive Medicine Bulletin. 2015:14(6): 451-457.

Okunade K, Nwogu C, Oluwole A and Anorlu R. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the out-patient clinics of a university teaching hospital in Lagos, Nigeria. Pan Afr Med J. 2017; 28:227.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch X and De Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99.

Nejo Y, Olaleye D and Odaibo G. Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria. Arch Basic Appl Med. 2018;6(1):105-112.

Kabir A, Bukar M, Nggada H, Rann H, Gidado A and Musa A. Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. Pan Afr Med J. 2019; 33:284.

Derbie A, Mekonnen D, Yismaw G, Biadglegne F, Van ostade X and Abebe T. Human papillomavirus in Ethiopia. Virusdisease. 2019;30(2):171-179.

Banura C, Mirembe F, Katahoire A, Namujju P, Mbonye A and Wabwire F. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agents Cancer. 2011;6(1):11.

Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreasen A, Changalucha J, Mayaud P, Kapiga S, Gumodoka B, Hayes R and De Sanjosé S. High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex Transm Infect. 2013;89(5):358-65.

Balogun F. The state of adolescent immunization in Nigeria: a wake up call for all stakeholders. Pan Afr Med J. 2019; 33:294.

Refbacks

  • There are currently no refbacks.